We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ADC Drops Goal of Accelerated Approval for Cami in Hodgkins
ADC Drops Goal of Accelerated Approval for Cami in Hodgkins
ADC Therapeutics’ Cami (camidanlumab tesirine), an investigational antibody-drug conjugate, has hit the end of its quest to gain accelerated approval for adults with heavily pretreated Hodgkin lymphoma, but — if ADC can find a willing partner — it may live on as a combination treatment for solid tumors.